A Fatty Acid from the Diatom Phaeodactylum tricornutum is Antibacterial Against Diverse Bacteria Including Multi-resistant Staphylococcus aureus (MRSA)

A Fatty Acid from the Diatom Phaeodactylum tricornutum is Antibacterial Against Diverse Bacteria Including Multi-resistant Staphylococcus aureus (MRSA)
复制标题

DOI:
10.1007/s10126-008-9118-5
复制
发表时间:
2009-02-01
影响因子:
3
通讯作者:
Smith, Valerie J.
Smith, Valerie J.
中科院分区:
生物学2区
文献类型:
--
作者:
Desbois, Andrew P.;Mearns-Spragg, Andrew;Smith, Valerie J.

文献摘要

被引文献

相似文献

病原菌,如耐多药金黄色葡萄球菌(MRSA),对大多数传统抗生素不敏感,正在引起全球医疗机构的日益关注。用于生物医学开发的新型抗菌化合物的发现是对抗这些问题细菌的一种途径。已知海洋真核微藻产生许多有用的产物,但在寻找新的抗生素化合物方面很少引起注意。据报道,海洋硅藻三角褐指藻的细胞裂解物在体外显示出抗菌活性,但负责的化合物尚未完全鉴定。本文采用柱层析和反相高效液相色谱法,分离了一种具有抗菌作用的脂肪酸。质谱和H-1-核磁共振光谱显示它是多不饱和脂肪酸,二十碳五烯酸(EPA)。我们表明,EPA是积极的对一系列革兰氏阳性和革兰氏阴性细菌,包括MRSA,在微摩尔浓度。这些数据表明,它可以在耐药细菌感染的局部和全身治疗中找到应用。
Pathogenic bacteria, such as multidrug-resistant Staphylococcus aureus (MRSA), which are not susceptible to most conventional antibiotics, are causing increased concern in healthcare institutions worldwide. The discovery of novel antibacterial compounds for biomedical exploitation is one avenue that is being pursued to combat these problematic bacteria. Marine eukaryotic microalgae are known to produce numerous useful products but have attracted little attention in the search for novel antibiotic compounds. Cell lysates of the marine diatom, Phaeodactylum tricornutum Bohlin, have been reported to display antibacterial activity in vitro, but the compounds responsible have not been fully identified. In this paper, using column chromatography and reversed-phase high-performance liquid chromatography, we report the isolation of an antibacterial fatty acid. Mass spectrometry and H-1-nuclear magnetic resonance spectroscopy revealed it to be the polyunsaturated fatty acid, eicosapentaenoic acid (EPA). We show that EPA is active against a range of both Gram-positive and Gram-negative bacteria, including MRSA, at micromolar concentrations. These data indicate that it could find application in the topical and systemic treatment of drug-resistant bacterial infections.